InterventionsReview

Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis

Fig. 1. PRISMA flow diagram of the included studies
Open the figure at full size
Fig. 1. PRISMA flow diagram of the included studiesPRISMA flow diagram of the included studiesHegaz et al.

BMC Endocrine Disorders

The paper

Tanta University · St. Joseph’s University Medical Center

BMC Endocrine Disorders · 15 Sep 2026

doi.org/10.1186/s12902-026-02538-xPubMed 42750018

More on GLP1R